Antabuse moves into clinical trial for people with RP
Disulfiram (Antabuse), FDA-approved for deterring alcohol, is in a phase 1 trial at the University of Washington to improve vision in retinitis pigmentosa.
Search
Search results
Webinar: Visual hallucinations and Charles Bonnet syndrome
Prof Dominic Ffytche will provide an explanation of what Charles Bonnet Syndrome is, the science behind it, and share some potential coping strategies for people who experience visual hallucinations.
Join our mailing list
Sign up to receive regular updates from Retina UK and learn more about the most innovative research and technology news, upcoming events, fundraising and support services available.
Meet our volunteers: Cindy Peacock
“Being part of something and feeling that you are not alone,” are just two of the positive benefits Cindy Peacock says she experiences as a volunteer with Retina UK.
Quiz for Retina UK
Do you know your facts from your fiction? Host a quiz for Retina UK.
Growth factors
Growth factors are substances that promote the health and function of cells and tissues in the body.
Disappointing news from ProQR clinical trial for LCA10
ProQR has published the top-line results from its Phase 2/3 “Illuminate” trial of the RNA therapy sepofarsen for Leber congenital amaurosis type 10 caused by a specific mutation in the CEP290 gene.
Researcher profiles
Research into inherited retinal conditions is one of the key objectives of Retina UK.
Meet our Trustee: Lynda Cantor MBE, Hon President
Lynda Cantor was a founder member of the charity in 1975 and one of our original trustees
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.